Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295750 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT00295750 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 620 participants.
The verdict
NCT00295750, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
The study was a three-arm, active-control, multi-centre, parallel group study.
Interventions
- DRUG Degarelix
- DRUG Leuprolide 7.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295750
The ClinicalTrials.gov registry entry for NCT00295750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT00295750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295750 about?
NCT00295750 is a clinical study titled "The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer". The study was a three-arm, active-control, multi-centre, parallel group study.
What is the current status of trial NCT00295750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2006-02. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00295750?
The interventions under investigation include: Degarelix (DRUG), Leuprolide 7.5 mg (DRUG).
Who is sponsoring clinical trial NCT00295750?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.